B Cell Lymphoma
News
Kymriah cost effectiveness depends on long-term outcomes
The value proposition for the pricey CAR T-cell therapy depends on whether the real-world outcomes are as good as the ones seen in clinical trials...
News
Pruritus linked to wide variety of cancers
The odds of specific cancers vary by race.
News
New mantle cell trials launching
At least four new mantle cell lymphoma trials were registered in Clinicaltrials.gov in August 2018.
News
Venetoclax label now includes MRD data
The MURANO trial showed high rates of minimal residual disease negativity in patients treated with the venetoclax combination.
News
MRD data added to venetoclax label
The U.S.
News
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
News
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
Fluoroquinolones are recommended for adults with cancer-related immunosuppression if they are at high risk of infection, according to an updated...
News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).
News
First CAR T-cell therapy approved in Canada
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
England green-lights coverage of one CAR T-cell therapy
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.